ArticleBlood cancer journal2013

(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.

K Duncan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.